About Incannex Healthcare
Incannex Healthcare ADR (ASX:IHL), (NASDAQ:IXHL) is a dynamic biopharmaceutical company focused on the development of innovative medical treatments. Addressing a wide range of unmet medical needs, Incannex's operations encompass research and development projects aimed at creating therapies in the fields of obstructive sleep apnea, traumatic brain injury, rheumatoid arthritis, and inflammatory lung diseases, among others. The company's objectives are rooted in advancing these projects through clinical trials, leveraging a blend of proprietary drug formulations and novel therapeutic approaches to improve patient outcomes. Incannex Healthcare is committed to navigating the complex regulatory pathways to bring their therapies from the lab to the global market, endeavoring to make a significant impact on healthcare and patient well-being.
Snapshot
Operations
Products and/or services of Incannex Healthcare
- Development of cannabinoid-based therapies for obstructive sleep apnea.
- Clinical trials for a treatment aimed at reducing lung inflammation in patients with COVID-19.
- Research into psychedelic compounds for mental health conditions.
- Innovation of therapies targeting traumatic brain injury and concussion.
- Development of anti-inflammatory treatments for chronic obstructive pulmonary disease.
- Creating cannabinoid formulations for pain management.
Incannex Healthcare executive team
- Mr. Joel Bradley LathamPresident, CEO & Executive Director
- Mr. Joseph SwanCFO, Treasurer & Secretary
- Dr. Luigi M. Barbato M.D.Chief Medical Officer
- Mr. Lekhram Changoer M.Sc.CTO & Member of Advisory Board
- Dr. Mark Bleackley Ph.D.Chief Scientific Officer, Head of Programs & Member of the Advisory Board
- Mr. John Michailidis B.Sc., EMBA, M.A.I.C.D.Chief Executive Officer of IncannexTM
- Natalie MayHead of Clinical Operations